Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Google Secures Pentagon AI Deal for Classified Projects 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
JERSEY, Channel Islands, May 09, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the UBS Global Healthcare Conference on Tuesday, May 23, 2017 at 10:30 a.m. Eastern Time at the Grand Hyatt New York. Also participating in the conference will be the Company’s Chief Financial Officer, Chris Lindop.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
